Format

Send to

Choose Destination
Pharmaceuticals (Basel). 2017 Sep 27;10(4). pii: E77. doi: 10.3390/ph10040077.

Procedures for the GMP-Compliant Production and Quality Control of [18F]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer.

Author information

1
German Cancer Research Center (DKFZ), Division of Radiopharmaceutical Chemistry, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. jens.cardinale@lbiad.lbg.ac.at.
2
ABX Advanced Biochemical Compounds GmbH, Heinrich-Glaeser-Strasse 10-14, 01454 Radeberg, Germany. rene.martin@abx.de.
3
German Cancer Research Center (DKFZ), Division of Radiopharmaceutical Chemistry, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. y.remde@dkfz.de.
4
German Cancer Research Center (DKFZ), Division of Radiopharmaceutical Chemistry, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. martin.schaefer@dkfz.de.
5
ABX Advanced Biochemical Compounds GmbH, Heinrich-Glaeser-Strasse 10-14, 01454 Radeberg, Germany. hienzsch@abx.de.
6
ABX Advanced Biochemical Compounds GmbH, Heinrich-Glaeser-Strasse 10-14, 01454 Radeberg, Germany. sandra.huebner@abx.de.
7
ABX Advanced Biochemical Compounds GmbH, Heinrich-Glaeser-Strasse 10-14, 01454 Radeberg, Germany. zerges@abx.de.
8
German Cancer Research Center (DKFZ), Division of Radiopharmaceutical Chemistry, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. h.marx@dkfz.de.
9
ABX Advanced Biochemical Compounds GmbH, Heinrich-Glaeser-Strasse 10-14, 01454 Radeberg, Germany. hesse@abx.de.
10
German Cancer Research Center (DKFZ), Division of Radiopharmaceutical Chemistry, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. k.weber@dkfz.de.
11
ABX Advanced Biochemical Compounds GmbH, Heinrich-Glaeser-Strasse 10-14, 01454 Radeberg, Germany. smits@abx.de.
12
ABX Advanced Biochemical Compounds GmbH, Heinrich-Glaeser-Strasse 10-14, 01454 Radeberg, Germany. hoepping@abx.de.
13
ABX Advanced Biochemical Compounds GmbH, Heinrich-Glaeser-Strasse 10-14, 01454 Radeberg, Germany. marco.mueller@abx.de.
14
German Cancer Research Center (DKFZ), Division of Radiopharmaceutical Chemistry, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. o.neels@dkfz.de.
15
German Cancer Consortium (DKTK), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. o.neels@dkfz.de.
16
German Cancer Research Center (DKFZ), Division of Radiopharmaceutical Chemistry, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. k.kopka@dkfz.de.
17
German Cancer Consortium (DKTK), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. k.kopka@dkfz.de.

Abstract

Radiolabeled tracers targeting the prostate-specific membrane antigen (PSMA) have become important radiopharmaceuticals for the PET-imaging of prostate cancer. In this connection, we recently developed the fluorine-18-labelled PSMA-ligand [18F]PSMA-1007 as the next generation radiofluorinated Glu-ureido PSMA inhibitor after [18F]DCFPyL and [18F]DCFBC. Since radiosynthesis so far has been suffering from rather poor yields, novel procedures for the automated radiosyntheses of [18F]PSMA-1007 have been developed. We herein report on both the two-step and the novel one-step procedures, which have been performed on different commonly-used radiosynthesisers. Using the novel one-step procedure, the [18F]PSMA-1007 was produced in good radiochemical yields ranging from 25 to 80% and synthesis times of less than 55 min. Furthermore, upscaling to product activities up to 50 GBq per batch was successfully conducted. All batches passed quality control according to European Pharmacopoeia standards. Therefore, we were able to disclose a new, simple and, at the same time, high yielding production pathway for the next generation PSMA radioligand [18F]PSMA-1007. Actually, it turned out that the radiosynthesis is as easily realised as the well-known [18F]FDG synthesis and, thus, transferable to all currently-available radiosynthesisers. Using the new procedures, the clinical daily routine can be sustainably supported in-house even in larger hospitals by a single production batch.

KEYWORDS:

PET; PSMA; [18F]PSMA-1007; automation; fluorine-18; prostate cancer

Conflict of interest statement

René Martin, Alexander Hoepping, Sandra Hübner, Anna-Maria Zerges, Rene Smits, Ronny Hesse, A. Hoepping and M. Müller are employees of ABX advanced biochemical compounds GmbH. [F]PSMA-1007 is the subject of a patent application by DKFZ Heidelberg with contributing inventors Jens Cardinale and Klaus Kopka et al. The one-step synthesis method using Precursor 3 is the subject of a patent application by ABX advanced biochemical compounds with contributing inventors René Martin, Ronny Hesse, Rene Smits, Marco Müller and Alexander Hoepping.

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center